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Aims To determine if an intensified form of heart failure management programme (INT-HF-MP) based on individual pro-
filing is superior to standard management (SM) in reducing health care costs during 12-month follow-up (primary
endpoint).
...................................................................................................................................................................................................
Methods
and results
A multicentre randomized trial involving 787 patients (full analysis set) discharged from four tertiary hospitals with
chronic HF who were randomized to SM (n= 391) or INT-HF-MP (n= 396). Mean age was 74 ± 12 years, 65% had
HF with a reduced ejection fraction (31.4 ± 8.9%) and 14% were remote-dwelling. Study groups were well matched.
According to Green, Amber, Red Delineation of rIsk And Need in HF (GARDIAN-HF) profiling, regardless of loca-
tion, patients in the INT-HF-MP received a combination of face-to-face (home visits) and structured telephone sup-
port (STS); only 9% (‘low risk’) were designated to receive the same level of management as the SM group. The
median cost in 2017 Australian dollars (A$1 equivalent to EUR e0.7) of applying INT-HF-MP was significantly
greater than SM ($152 vs. $121 per patient per month; P< 0.001), However, at 12 months, there was no difference
in total health care costs for the INT-HF-MP vs. SM group (median $1579, IQR $644 to $3717 vs. $1450, IQR
$564 to $3615 per patient per month, respectively). This reflected minimal differences in all-cause mortality
(17.7% vs. 18.4%; P= 0.848) and recurrent hospital stay (18.6 ± 26.5 vs. 16.6 ± 24.8 days; P= 0.199) between the
INT-HF-MP and SM groups, respectively.
...................................................................................................................................................................................................
Conclusion During 12-months follow-up, an INT-HF-MP did not reduce healthcare costs or improve health outcomes relative
to SM.
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Introduction
Based on a robust evidence-base (Level 1A), the latest ESC guidelines
recommend that patients with heart failure (HF) are enrolled in a
multidisciplinary care management programme (MP) to reduce the
risk of HF hospitalization and mortality.1 Findings from contemporary
systematic reviews and meta-analyses2,3 suggest that there is a cogent
argument for establishing such multidisciplinary care in the post-
discharge setting via HF nurses and home visits; particularly to im-
prove ‘all-cause’, as opposed to HF-specific, outcomes. Previously,
we conducted a multicentre, head-to-head trial of home-based vs.
specialist clinic-based HF management that applied the same nurse-
led, multidisciplinary care.4 Consistent with a broader analysis of this
strategy across the spectrum of heart disease,5 home-based manage-
ment was superior in reducing hospital stay and prolonging survival in
the longer-term6; and health economic analysis demonstrated it to
be more cost-effective compared to specialist HF clinics.7
Despite their overall efficacy, however, HF-MPs are being challenged
further to reduce high levels of morbidity and mortality. At the same
time, an increasingly older and more clinically complex patient popula-
tion are making greater demands on limited healthcare resources.8,9
We postulated that an initial investment in more intensive manage-
ment directed towards higher risk HF patients would yield cost-savings
overall via less costly hospital stay in the medium-to-longer term.
Therefore, we tested the hypothesis that ‘a more intensive, nurse-led,
post-discharge, multidisciplinary, HF management programme incor-
porating outreach home-based intervention enhanced by structured
telephone support (STS) (INT-HF-MP) would be superior to standard
management (SM) incorporating home-based care and STS for metro-
politan and remote-dwelling patients, respectively, in reducing the total
cost of healthcare during 12-month follow-up’.
Methods
Study design and participants
The Which Heart failure Intervention is most Cost-effective in reducing
Hospital stay (WHICH? II) Trial was a multicentre, randomized trial
that adheres to the CONSORT guidelines for a pragmatic trial10 and
the Declaration of Helsinki for ethical practice—(ANZCTR
12613000921785).
Participant recruitment commenced on August 28th 2013 from four
tertiary hospitals in Adelaide, Melbourne and Sydney, Australia. The last
participant was discharged from hospital in February 2016 and minimum
12-month follow-up completed in February 2017. Ethics approval was
obtained from Central Northern Adelaide Health Service (HREC/13/
TQEHLMH/99), Melbourne Health (HREC 2013.145), St Vincent’s
Hospital Sydney (HREC/13/SVH/313) and Prince of Wales Hospital,
Sydney (HREC/13/SVH/313). All participants gave written informed con-
sent. Participants were enrolled by registered nurses at each site. Patients
aged >_ 18 years admitted to participating hospitals were eligible if they
had a cardiologist-confirmed diagnosis of chronic HF based on echocardi-
ography and persistent exercise intolerance [New York Heart
Association (NYHA) Class II–IV], a history of >_1 admission for acute
decompensated HF (including the index admission) and were being dis-
charged to home. Patients were only excluded if they had a terminal con-
dition and/or were unable to provide fully informed consent. Patients
from non-English speaking background were included and supported by
translation services when needed.
Group randomization
Blinded, computer-generated randomization was applied by an indepen-
dent data management team via telephone. A pre-determined random-
ization sequence, with block groups for each study site and stratified
according to presence of HF with reduced or preserved ejection fraction
[HFrEF or HFpEF, respectively, based on a left ventricular ejection frac-
tion (LVEF) <45% or >_45%] and metropolitan-dwelling (<30 km and/
or <45 min travel time to a patient’s home) or remote-dwelling status, al-
located 407 and 402 patients, respectively, to the INT-HF-MP and SM
groups (see Figure 1).
Study data
All study data were collected via protocol-following registered nurses
with standardized case-report forms (see Supplementary material online,
Appendix I). This included comprehensive demographic and clinical profil-
ing (including HF history and hospital management) via a combination of
medical record review, patient interview and validated instruments. The
latter comprised assessment of cognition, depressive symptoms, self-care
abilities, physical strength, and level of (age-adjusted) multimorbidity via
the Montreal Cognitive Assessment (MoCA) Tool,11 two-item Arrol
tool,12 European Self-Care Behaviour Scale,13 handgrip strength via a cali-
brated manometer (hydraulic hand dynamometer SH5001) and Charlson
Comorbidity Index Score,14 respectively. Brain natriuretic peptide (BNP)
levels were also obtained initially using the Alere Heart Check Meter Kit
(since discontinued by the manufacturer) and then the Alere Triage
MeterPro immediately prior to index hospital discharge.
Post-discharge management
All patients were managed within the Australian healthcare system that
provides free or subsidized (depending on income) access to high level
management including primary and tertiary care, pharmacological treat-
ment, devices and allied health services. The nature and intensity of post-
discharge management depended on a patient’s home location and group
assignment (see Figure 2).
As per local guidelines,15 SM was determined by each patient’s home
location. Those within reach of the hospital’s pre-existing HF service
Figure 1 CONSORT flow-chart.
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..received follow-up care from experienced HF nurses who applied multi-
disciplinary, home-based intervention (minimum of one home visit within
7–14 days) post-index discharge, including access to specialist cardiology
support and referral to additional support (e.g. pharmacist review and ex-
ercise programs). Those living remotely (n= 113) received STS via the
National Heart Foundation of Australia’s National Health Information
Service—Call Centre utilized in the previously reported CHAT Study.16
In order to protect the integrity of SM, minimal contact or monitoring of
the activities by the HF-MP teams was applied.
As part of the study intervention, those allocated to the INT-HF-MP
were initially profiled prior to hospital discharge according to the Green,
Amber, Red Delineation of rIsk And Need tool17 adapted to HF
(GARDIAN-HF—see Supplementary material online, Figure S1 and Table
S1), to determine their level of risk of premature mortality or recurrent
hospitalization (based on patterns of outcome in the WHICH? Trial).4 A
critical component of this profiling is the detection of ongoing clinical in-
stability [automatically classified as high risk (Red) requiring proactive
management]. All metropolitan-dwelling patients received a 7–14 day
home-visit. Those remote-dwelling patients designated GARDIAN-HF
Red also received a home visit (mean 270 km) and the remainder a
phone-call review at 7–14 days (see Supplementary material online, Table
S2). GARDIAN-HF status was updated at the 7–14 day review, and auto-
mated reports sent to each patient’s healthcare team. As shown in Figure
3 a combination of repeat home visits and STS (via an automated
GARDIAN-ANGEL system to flag alerts and communications with the
HF Nurse) were then applied according to GARDIAN-HF Status (see
Supplementary material online, Figures S2 and S3). Due to a combination
of patient requests (to reduce phone contact) and high clinical vigilance,
levels of STS were similar for Red and Amber GARDIAN-HF designated
patients. GARDIAN-HF status was reassessed at 6 months (noting mini-
mal probability of reclassification downwards). For those aged <75 years,
the same methods used at baseline (where possible) were reapplied to
obtain BNP levels at 3, 6, and 9 months, with automated clinical alerts and
recommendations for treatment titration if the BNP remained elevated
(>600 pg/mL). During 12 month follow-up, only 7% of patients subject to
incremental STS demonstrated no signs of clinical instability; those desig-
nated GARDIAN-HF Red Status the most labile (see Supplementary ma-
terial online, Figure S4) and requiring either urgent review (12% of
contacts) or an emergency intervention (1%—Supplementary material
online, Figure S5).
Study endpoints
All data were evaluated by study investigators masked to group allocation.
The primary endpoint was total healthcare costs during 12-month follow-
up. These were calculated in 2017 Australian dollars (A$1 is equivalent to
EUR e0.7). As described in Supplementary material online, Appendix II,
they comprised three key cost components: (i) hospital care (including
non-admitted emergency department visits, unplanned and elective hospi-
tal admissions, rehabilitation, palliative care, and outpatient reviews/proce-
dures); (ii) community care (including primary care visits, allied health care
and nursing home stay); and (iii) HF-specific management that, in the INT-
HF-MP group reflected the additional costs of applying extra home visits
and STS to remote and metropolitan-dwelling patients, respectively, in ad-
dition to serial BNP monitoring among patients aged <75 years. Major sec-
ondary endpoints were: (i) the pattern of all-cause rehospitalization and
related hospital stay with further delineation of unplanned vs. elective,
cardiovascular-disease (CVD) related and HF-related hospitalization; (ii)
all-cause mortality, (iii) event-free survival as expressed by the number of
days alive and out-of-hospital (DAOH), and (iv) change in generic
(EuroQol 5-dimensions/5-levels questionnaire, EQ-5D-5L)18 and HF-
specific (Kansas City Cardiomyopathy Questionnaire, KCCQ)19 health-
related quality of life from baseline to 12 months.
Statistical analyses
All analyses were performed, in blinded fashion, according to a prospec-
tively planned Statistical Analysis Plan (see Supplementary material online,
Appendix III) by the trial statistician. Health outcome data from the original
Figure 2 Study design and clinical management.
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.WHICH? Trial4 were used to inform study power calculations. A total of
400 participants in each group provided >85% power (2-sided alpha
0.05) to detect a >15% group differential in total healthcare cost and all-
cause hospital stay. Data for all four sites were pooled. Discrete variables
were summarized by frequencies and percentages and continuous vari-
ables by standard measures of central tendency and dispersion using
mean ± standard deviation (SD) and medians [inter-quartile range (IQR)].
All efficacy analyses were undertaken on a full analysis set basis. Total
healthcare costs, the number of recurrent admissions and days of hospital
stay were compared between groups using adjusted negative binomial
regression after adjusting for length of follow up (events per participant
per month) and stratification criteria (HF type and home location).
Kaplan-Meier survival analyses were used to examine all-cause mortality,
with a log-rank test used for between group comparisons. The fraction of
maximum possible vs. actual DAOH (all forms of hospitalization) was
compared with the Mann–Whitney U test. Other between group com-
parisons were assessed by Student’s t-tests (normally distributed continu-
ous data), Mann–Whitney U test (non-normally distributed continuous
data) and v2 test [with calculation of odd ratios (OR) and 95% confidence
intervals (CI)] where appropriate.
Results
Baseline profile
As shown in Figure 1, a total of 787/809 patients formed the full analy-
sis set (following early death and withdrawal) and were randomized
to the INT-HF-MP (n= 396) or SM (n= 391). Overall, Table 1 shows
that this was a typically older cohort (aged 74 ± 12 years), of whom,
41% were female. Factors likely to complicate HF management in-
cluded low education levels (76%), living alone (40%) or having a
non-English speaking background (20%). Geographically, 14% of pa-
tients lived remotely from specialist health services (range 30 to
1154 km). The majority of patients, most of whom (80%) presented
as NYHA Class III/IV, had a history of hypertension (76%) and/or cor-
onary artery disease (61%) and had been treated for HFrEF (65%) or
HFpEF (35%) for an average of 47 months. Of the 253 patients (32%)
with a secondary diagnosis of HF, ischaemic heart disease (28%), ar-
rhythmias (19%—primarily AF) and respiratory disease (10%) ac-
counted for half these presentations. Levels of multimorbidity were
high with >50% of patients affected by concurrent mild cognitive
impairment, anaemia, atrial fibrillation, moderate-to-severe renal im-
pairment and/or depressive symptoms. Overall, the mean (age-ad-
justed) Charlson Comorbidity Index Score was 6.9 ± 2.4. Following a
median of 6 (IQR 4 to 11) days index hospitalization, the majority
were assessed as NYHA Class II (72%) and were prescribed an ap-
propriate combination of pharmacotherapy comprising diuretics
(90%), beta-blockers (81%) and renin-angiotensin-aldosterone sys-
tem (RAAS) blockade (70%) relevant to their HF type/expert recom-
mendations1 and individual tolerance to such therapy. Overall, the
two groups were very well matched according to their baseline pro-
file (see Table 1).
Figure 3 Pattern of intensified management according to GARDIAN-HF.
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Table 1 Baseline profile
All INT-HF-MP SM
(n5 787) (n5 396) (n5391)
Sociodemographic profile
Age (years) 74 ± 12 74 ± 11 74 ± 12
Female 325 (41%) 164 (41%) 161 (41%)
Living alone 314 (40%) 167 (42%) 147 (38%)
Remote dwelling 113 (14%) 60 (15%) 53 (14%)
<12 years of education 602 (76%) 295 (74%) 307 (79%)
English not first language 154 (20%) 83 (21%) 71 (18%)
Risk profile
BMI (kg/m2)—n= 786 29.8 ± 7.0 29.9 ± 7.4 29.6 ± 6.5
Current smoker 119 (15%) 57 (14%) 62 (16%)
Type 2 diabetes 348 (44%) 166 (42%) 182 (47%)
Hypertension 598 (76%) 298 (75%) 300 (77%)
Heart failure profile
Duration of HF (months) 23 (IQR 9–61) 24 (IQR 9–65) 22 (IQR 8–58)
LVSD 509 (65%) 259 (65%) 250 (64%)
(LVEF %) 31.4 ± 8.9 31.4 ± 9.1 31.4 ± 8.7
NYHA class III/IV 222 (28%) 111 (28%) 111 (28%)
Elevated BNP—n= 761 389 (51%) 195 (50%) 194 (52%)
Prior HF admission (12 months) 472 (60%) 228 (58%) 244 (62%)
Clinical profile
Systolic BP (mm/Hg) 135 ± 27 134 ± 27 136 ± 27
Diastolic BP (mm/Hg) 76 ± 16 76 ± 16 76 ± 16
Heart rate (beats/min) 86 ± 24 86 ± 24 85 ± 23
Acute pulmonary oedema 254 (32%) 126 (32%) 128 (33%)
Coronary artery disease 479 (61%) 226 (57%) 253 (65%)
Depressive symptoms 512 (65%) 247 (62%) 265 (68%)
eGFR <60 ml/min/1.73 m2—n= 786 471 (60%) 242 (61%) 229 (59%)
Mild cognitive impairment—n= 576 330 (57%) 177 (60%) 153 (54%)
Anaemia (sex-specific)—n= 786 416 (53%) 212 (54%) 204 (52%)
Atrial fibrillation 428 (54%) 208 (53%) 220 (56%)
Cerebrovascular disease 169 (21%) 78 (20%) 91 (23%)
Sleep disorders 132 (17%) 68 (17%) 64 (16%)
Charlson Comorbidity Score 6.9 ± 2.4 6.8 ± 2.4 6.9 ± 2.4
CRT/ICD 150 (19%) 77 (19%) 73 (19%)
In-hospital management
Principal diagnosis of HF 534 (68%) 268 (68%) 266 (68%)
Length of stay (days) 6 (IQR 4–11) 6 (IQR 4–11) 7 (IQR 4–11)
Critical care (days) 3 (IQR 0–7) 3 (IQR 0–7) 2 (IQR 0–7)
Pharmacotherapy
Diuretic 709 (90%) 360 (91%) 349 (89%)
Beta-blocker 634 (81%) 322 (81%) 312 (80%)
RAAS blockade 553 (70%) 276 (70%) 277 (71%)
Anti-platelet 412 (52%) 214 (54%) 198 (51%)
Anti-coagulant 368 (47%) 190 (48%) 178 (46%)
Nitrate 235 (30%) 119 (30%) 116 (30%)
Digoxin 187 (24%) 93 (24%) 94 (24%)
Anti-arrhythmic agent 105 (13%) 52 (13%) 53 (14%)
There were no statistical differences between INT-HF-MP and SM groups, except for the comparison of history of coronary artery disease (P= 0.028).
Anaemia, haemoglobin (g/L) <130 males <120 females; BMI, body mass index; BNP, b-type natriuretic peptide; BP, blood pressure; CHF, chronic heart failure; eGFR, estimated
glomerular filtration rate; Elevated BNP, >600 pg/mL; LVEF, left ventricular ejection fraction; LVSD, left ventricular systolic dysfunction; NYHA, New York Heart Association;
CRT, cardiac resynchronization therapy; ICD, implantable cardiac defibrillator; RAAS, renin-angiotensin-aldosterone system.
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Healthcare costs
Total healthcare costs for the two groups combined was >A$20 mil-
lion during 12 months follow-up. Figure 4 compares the total cost and
three specific components of healthcare during 12-month follow-up
for the two groups (see Supplementary material online, Table S3).
The overall cost of applying HF-specific management per patient per
month was greater for the INT-HF-MP compared to SM group (me-
dian $152, IQR $132 to $164 vs. $121, IQR $121 to $121, respec-
tively; P< 0.001). For the primary endpoint, during 323 ± 94 days
follow-up, the INT-HF-MP group accumulated total healthcare costs
of $1579 (IQR $644 to $3717) per patient per month. This com-
pared to a slightly lower cost of $1450 (IQR $564 to $3615) per pa-
tient per month during 326 ± 91 days of follow up in the SM group
(P= 0.336). Accordingly, there were no differences in the cost of
hospital-based ($1109, IQR $198 to $3069 vs. $997, IQR $153 to
$3002 per patient per month; P= 0.445) or community-based health-
care costs ($265, IQR $214 to $317 vs. $266, IQR $219 to $334;
P= 0.893) for the INT-HF-MP and SM groups, respectively.
Additionally, irrespective of randomization strategy, there was a sig-
nificant difference in the hospital-based costs between those with
HFpEF and HFrEF, but not in respect to community-based healthcare
or HF-specific management costs (see Supplementary material on-
line, Table S4).
Survival and hospitalization
During 12-month follow-up, a total of 142 (18%) patients died; com-
prising 89/396 (23%), 52/303 (17%), and 1/88 (1.1%) patients initially
categorized as Red, Amber, or Green respectively according to
GARDIAN-HF criteria. According to group allocation, 70/396
(17.7%) patients in the INT-HF-MP group vs. 72/391 (18.4%) patients
in the SM group (P= 0.848) died (Figure 5). Overall, the study cohort
accumulated 2,204 hospital events comprising 485 non-admitted
emergency department visits, 374 (944 length of stay days) elective
admissions and 1178 (9909 days) unplanned admissions, in addition
to 145 (2621 days) and 22 (384 days) admissions, respectively, re-
lated to rehabilitation and palliative care (see Supplementary material
online, Figure S6). According to initial GARDIAN-HF status, patients
categorized as Red, Amber, and Green accumulated a mean of 20,
18, and 5.4 days of all-cause hospital stay. Table 2 compares the pat-
tern of recurrent hospitalization and related stay according to group
assignment. Overall, 251 (63%) INT-HF-MP patients compared to
222 (57%) SM patients had >_1 unplanned hospitalization. There were
no significant differences between the rate of unplanned, CVD-
related, HF-specific and total hospitalization and related hospital stay
between the two groups. Based on equivalent levels of mortality and
hospital stay, there was also no significant difference between groups
in respect to all-cause DAOH (304 ± 100 vs. 309 ± 96 days, repre-
senting 84.9% vs. 86.1% of actual/maximal DAOH in the INT-HF-MP
vs. SM groups, respectively; P= 0.493). Importantly, the pattern of
survival and hospitalization according to group assignment was similar
for all four study sites.
Health-related quality of life
Baseline EQ-5D-5L scores were similar between the two groups.
Among survivors with repeat scores at 12 months (270 INT-HF-MP
and 258 SM patients), mean change in EQ-5D-5L scores were not sig-
nificantly different (0.01, 95% CI -0.03 to 0.04 vs. 0.03 95% CI 0.0 to
0.07; P= 0.221). Similarly, baseline HF-specific health-related quality
of life KCCQ scores and the changes from baseline to 12 months
were similar between the two groups in all indices measured except
for a greater improvement in KCCQ Self-efficacy subscale in INT-
HF-MP patients (35, 95% CI 32 to 39 vs. 29, 95% CI 26 to 33;
P= 0.023) from baseline to 12-month (see Supplementary material
online, Table S5).
Discussion
Despite a substantial investment in profiling patient risk and then ap-
plying a combination of home visits and STS (regardless of location)
Figure 4 Healthcare costs according to group: Values are ex-
pressed in $A as median per patient per month. F/U, follow-up.
Figure 5 All-cause survival according to group.
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and supported by BNP monitoring where appropriate, compared to
less intensive and costly HF management (representing the current
gold-standard), there was no difference in the primary endpoint of
total healthcare costs during 12 months follow-up. This outcome re-
flected a lack of expected impact on the pattern of recurrent hospi-
talization (of any type) and associated stay and survival by the study
intervention. If anything, nearly all study endpoints tended to favour
SM; comprising HF nurse home visits for metropolitan-dwelling pa-
tients and STS for regional dwelling patients (regardless of risk status).
Incremental management, as applied in the mainly high risk 396 pa-
tients assigned to INT-HF-MP was not insubstantial; comprising an
additional 72 home visits to remote dwelling patients (noting the lo-
gistical difficulty of applying repeat home visits in this cohort living
up >1000 km away), 7208 STS contacts (>10% of which prompted
additional management) and 421 BNP surveillance tests over and
above SM. Nevertheless, beyond the primary and secondary end-
point comparisons, there were minimal clinical differences between
survivors at 12 months (see Supplementary material online, Table S6).
A number of issues arising from these findings require commen-
tary. Firstly, as part of pre-specified analyses, we determined that the
pattern of healthcare costs and outcomes in the two groups was con-
sistent across all four study sites and regardless of when a participant
was randomized into the study; the latter indicating a lack of interven-
tional ‘fatigue’ over time. A critical component of the study interven-
tion was GARDIAN-HF profiling (to direct a combination of home
visits and STS regardless of patient location). Based on initial profiling
(during index admission) there was a clear gradient in subsequent
hospitalization and survival from Green to Red status; indicating clear
potential to attenuate elevated risk of poor outcomes via the study
intervention. A consistent feature of systematic reviews and meta-
analyses of the evidence underpinning the application of HF-MPs has
been the superiority of nurse-led, multidisciplinary management ap-
plied via home visits.2,3 This was applied as SM in this trial. Whilst
we’ve previously demonstrated the incremental benefits of this ap-
proach relative to a purely specialist HF clinic approach (via the origi-
nal WHICH? Trial4,6,7), it appears clear that face-to-face programs
are superior to those applying remote management (i.e. STS alone).3
It is certainly possible that the addition of STS as part of the study in-
tervention (despite our best intentions and a dedicated communica-
tions and alert protocol—the GARDIAN-ANGEL system) interfered
....................................................................................................................................................................................................................
Table 2 Comparison of hospital events
INT-HF-MP SM Group comparisons
(n5 396) (n5391)
Study follow-up
Mean days of follow-up 323 ± 94 326 ± 91 P= 0.986
Unplanned admissions 595 j 5344 days 583 j 4565 days
Episodes/participant 1.5 ± 1.9 1.5 ± 2.1 P= 0.915
Days/participant 13.5 ± 21.3 11.7 ± 19.3 P= 0.204
Median days of stay per event 12 (IQR 6 to 30) 13 (IQR 5 to 28) P= 0.587
CVD-related admissions 424 j 3241 days 425 j 2859 days
Episodes/participant 1.1 ± 1.5 1.1 ± 1.7 P= 0.880
Days/participant 8.2 ± 14.2 7.3 ± 14.4 P= 0.440
Median days of stay per event 10 (IQR 4 to 19) 9 (IQR 4 to 21) P= 0.765
HF (primary) admissions 213 j 2006 days 182 j 1486 days
Episodes/participant 0.5 ± 1.0 0.5 ± 1.0 P= 0.298
Days/participant 5.1 ± 11.5 3.8 ± 10.2 P= 0.198
Median days of stay per event 12 (IQR 6 to 21) 8 (IQR 4 to 19) P= 0.228
All admissions 778 j 5820 days 774 j 5033 days
Episodes/participant 2.0 ± 2.3 2.0 ± 2.8 P= 0.934
Days/participant 14.7 ± 21.7 12.9 ± 20.1 P= 0.221
Median days of stay per event 12 (IQR 5 to 26) 11 (IQR 4 to 27) P= 0.462
Rehabilitation 70 j 1306 days 75 j 1315 days
Episodes/participant 0.2 ± 0.4 0.2 ± 0.5 P= 0.649
Days/participant 3.3 ± 10.8 3.4 ± 10.0 P= 0.930
Median days of stay per event 14 (IQR 7 to 27) 19 (IQR 12 to 30) P= 0.082
Palliative care 12 j 242 days 10 j 142 days
Episodes/participant 0.03 ± 0.19 0.03 ± 0.16 P= 0.701
Days/participant 0.6 ± 5.1 0.4 ± 3.2 P= 0.417
Median days of stay per event 24 (IQR 4 to 29) 7 (IQR 4 to 23) P= 0.393
Non-admitted ED visits 249 236
Episodes/participant 0.6 ± 1.3 0.6 ± 1.1 P= 0.766
Follow-up was censored for death and lost to follow-up.
2346 P.A. Scuffham et al.
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with standard face-to-face management. Another strong possibility is
that we reached a ‘threshold effect0 of management, whereby addi-
tional support, surveillance and advice (with the prospect of invoking
the previously described phenomenon of a counter-productive ‘clini-
cal cascade’ effect20) counter-balanced any potential benefits of more
intensive intervention. The fact that this was a particularly old and
fragile HF patient cohort with substantive multimorbidity (with signifi-
cantly longer length of stay per episode) may be relevant to the ob-
served lack of interventional effect. In a recent analysis of the overall
benefits of nurse-led, home-based intervention in all forms of chronic
heart disease,5 we did observe the potential for worse outcomes
when this model of care was applied to older individuals with high
levels of multimorbidity. Given the high prevalence of AF in this co-
hort (around 50%) it is worth noting that many therapeutic options
(e.g. CRT) are not known to be effective in affected individuals.1
Keeping in mind that health goals may differ between age groups, it is
necessary to determine how we might implement new interventions
by adjusting previously successful modes of management, rather than
simply conceding to poor quality of care in this increasingly common
and challenging patient population.8,9 Pending the outcome of longer-
term follow-up of this cohort, according to group assignment, it will be
critical to understand who might still benefit from the study intervention.
There are few trials that have purposefully compared the same
type of HF management but modified the intensity of its application; a
notable exception being the three-armed (one control group vs. HF
nurse-led management applied in a moderately or intensive fashion)
COACH Study conducted by Jaarsma et al.21 Moreover, there is a
paucity of trials purposefully applying a ‘hybrid’ approach (i.e. combin-
ing home visits and STS). Although our trial cohort is markedly older
with greater multimorbidity (an expected difference given the two
studies being a decade apart), the COACH Study also failed to find
any benefits from applying HF management in a more intensive man-
ner.21 The challenge of further enhancing the cost-efficacy of current
HF-MPs, particularly in the setting of negative trials of remote moni-
toring techniques relative to SM22,23 remains unanswered.
As a pragmatic health services intervention trial undertaken in one
health system, there are some limitations to interpreting the veracity
and wider applicability of study findings. The patients, clinicians and
majority of research personnel involved in the trial were not (com-
pletely) blinded to group assignment; with potential loss of blinding
for endpoint adjudication if clinical reports indicated group assign-
ment. We relied on administrative data-sets and cross-referencing to
patient and clinician reports to verify study outcomes. We also pur-
posefully avoided monitoring or measuring the intensity and nature
of SM; relying upon our detailed understanding of the HF-MP being
applied at each site and excluding the application of home visits and
STS to regional-dwelling patients and metropolitan-dwelling patients,
respectively, and the lack of routine access to BNP monitoring. This
study was also conducted in Australia and the cost-dynamics of man-
agement may be different elsewhere. However, given the size, scope,
and consistency of study findings across four different hospitals and
HF services, they are likely to be relevant to other healthcare settings;
particularly when hospital costs remain the major component of HF-
related expenditure in high income countries.24
In conclusion, as part of one of the largest and most comprehen-
sive studies of its kind, we compared gold-standard HF management
with a more intensified version of the same that particularly targeted
those patients most at risk of recurrent hospitalization and prema-
ture mortality. Despite accurately identifying such patients (and ap-
plying a more costly and intensive form of HF management), this
investment failed to deliver better health outcomes and lower cost;
at least during 12 months follow-up.
Supplementary material
Supplementary material is available at European Heart Journal online.
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